Aprea Therapeutics (APRE) vs Imunon (IMNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Imunon is the larger company by market cap ($3.5 million vs $3.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APRE | IMNN |
|---|---|---|
| Share price | $0.229 | $0.5355 |
| Market cap | $3.25M | $3.47M |
| 1-day change | -53.56% | -5.22% |
| EPS (TTM) | $-0.57 | $-3.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-12.60M | $-14.50M |
| 52-week high | $1.49 | $4.35 |
| 52-week low | $0.2036 | $0.50 |
| Distance from 52-week high | -84.63% | -87.69% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1528.82% | +3074.60% |
| Average volume | 388.67K | 150.49K |
| Shares outstanding | 14.19M | 6.49M |
| Employees | 8 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Imunon
IMNN stock →Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
APRE vs IMNN FAQ
Which is bigger, Aprea Therapeutics or Imunon?
Imunon (IMNN) is larger, with a market capitalization of $3.47M compared with $3.25M for Aprea Therapeutics (APRE).
Are Aprea Therapeutics and Imunon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.